Iran to jab individuals against H1N1 for free

January 10, 2010

Courtesy by:

Iranian officials are preparing to mount a free campaign to inoculate at-risk individuals against A/H1N1 flu in the coming days.

Latest figures have revealed a considerable decline in the number of cases that had tested positive for the flu in Iran. No new deaths have been reported in the past two weeks.

Officials, however, predict upcoming waves of the disease in the world as well as Iran, bringing up the need for inoculating high-risk individuals against the disease.

“At-risk individuals such as pregnant women, immunocompromised patients, HIV positive individuals and those suffering from underlying diseases — such as heart, renal and respiratory disorders or active cancer, liver cirrhosis, uncontrolled diabetes, thalassemia, sickle cell anemia and morbid obesity — along with children aged younger than 19 and individuals who are incapable of excreting their sputum will receive the H1N1 vaccine,” said Minou Mohraz, the head of the Iranian association for infectious disease and a member of the National Influenza Committee.

She stressed that healthcare providers who are in close contact with affected patients are in the priority for receiving the vaccine.

Mohraz continued to say that the vaccine will be distributed by the Universities of Medical Sciences in different parts of the country free of charge in order to overcome any possible black-marketing of the drug.

She stressed that the quality of the vaccine has been approved by the Iranian Ministry of Health, suggesting that no certain complication would be reported.

The head of the Iranian association for infectious disease said healthy individuals do not need to be jabbed against A/H1N1, adding that following simple precautionary measure can ward off the flu in these individuals.

Iran produces first desferal pills

May 15, 2009

Courtesy by:

Iranian researchers have produced the world’s first desferal pills to treat iron overload in patients suffering from thalassemia.

A hereditary blood disease, Thalassemia is characterized by altered hemoglobin formation and anemia. Patients must receive blood transfusions every 2 to 4 weeks to alleviate anemia-related symptoms.

While transfusion improves the quality of life in thalassemic patients, it adds excess iron to the body, resulting in chronic iron overload.

These patients receive desferal (deferoxamine mesylate USP), an iron-chelating agent, shots to slow the accumulation of iron in their bodies.

The newly-developed pills have shown promising results in overcoming the need for 8 to 12 injections per day in thalssemic patients. They can also lower the pain commonly experienced following the use of desferal injections.

“The new desferal pills have received FDA approval and are going to be mass-produced in the coming 3 months,” said managing director of the Iranian thalassemia association Mohammad Reza Mashhadi.

Some 18,616 thalassemic patients have been registered in Iran the majority of whom live in northern and southern parts of the country.

Due to a national prevention program which screens couples for thalassemia traits before marriage, the number of newly diagnosed cases has considerably decreased in recent years.

%d bloggers like this: